ANIP News and Press, ANI Pharmaceuticals Inc. From 08/03/22

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Acebutolol Hydrochloride Capsules. ANI’s Acebutolol Hydrochloride Capsules are the generic version of the Reference Listed Drug (RLD) Sectral ® ...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company. “We are pleased to expand our generics product portfolio with the...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2022 financial results on Monday, August 8, 2022, prior to market open. Nikhil Lalwani, President and Chief Executive Office...

3 Pharmaceutical Stocks For Your Watchlist Right Now For investors wondering what are the best stocks to invest in today, pharmaceutical stocks would be an interesting play. On the whole, this part of the stock market is home to companies of varying sizes and specializations...

ANI Pharmaceuticals (NASDAQ:ANIP) said the U.S. Food and Drug Administration (FDA) approved its generic clorazepate dipotassium tablets used to manage anxiety disorders. The company said the clorazepate dipotassium tablets are a generic version of Tranxene. "The imminent launch and comme...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Clorazepate Dipotassium Tablets. ANI’s Clorazepate Dipotassium Tablets ...

ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients PR Newswire Partnership drives commercial excellence through precision engagement to benefit patients in need of options BAUDETTE, Minn. and PLEASANTON, Calif. ,...

ANI Pharmaceuticals (NASDAQ:ANIP) on Thursday said it plans to stop operations at its Oakville, Canada manufacturing plant by Q1 2023. The biopharmaceutical company said it would move most of the products made or packaged in Oakville to one of its three U.S. sites. ANIP believes thi...

-- Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023 -- -- Action part of ongoing efforts to drive cost-competitiveness and deliver sustainable growth for generics business -- -- Preliminary estimate of $7 million to $8 million im...

ANI Pharmaceuticals (NASDAQ:ANIP) said it got U.S. Food and Drug Administration approval for its generic drug application for fludrocortisone acetate tablets. The Baudette, Minn.-based company's shares gained 6.1% to $32.39 in aftermarket trading on Wednesday. The approval was for A...